Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: Cancer as a risk factor

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 72-76

  Otten, Hans Martin M B ^a   Prins, Martin H ^a   Smorenburg, Susanne M ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Central venous catheterization; Chemotherapy; Incidence of venous thromboembolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; HORMONE;

ANTICOAGULANT THERAPY; BREAST CARCINOMA; CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CENTRAL VENOUS CATHETERIZATION; CONFERENCE PAPER; DRUG INDICATION; EMBOLISM; EMBOLISM PREVENTION; FEMALE; HUMAN; INCIDENCE; INDWELLING CATHETER; INTRAVENOUS CATHETER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS PREVENTION; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0034459758     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054167     Document Type: Conference Paper

References (37)

1. Hemostatic alterations in cancer patients
2. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis
3. Prevention of venous thromboembolism in general surgical patients
4. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery
5. Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery: A meta-analysis
6. Mechanisms of hypercoagulation in malignancy and during chemotherapy
7. Indices of hypercoagulation in cancer as compared with those with acute inflammation and acute infarction
8. Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis
9. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
10. The effect of very low dose warfarin on markers of hypercoagulation in metastatic breast cancer. Results from a randomized trial
11. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications
12. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer
13. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
14. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
15. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer
16. Venous thrombosis during multimodal treatment of primary breast carcinoma
17. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A EORTC breast cancer cooperative group study
18. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
19. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer
20. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for post-menopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
21. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the national surgical adjuvant breast and bowel project B-16
22. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
23. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
24. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: A study of 159 patients
25. Incidence and risk of thromboembolism during treatment of high-grade gliomas: A prospective study
26. The incidence and significance of thromboembolic complications in patients with high-grade gliomas
27. Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma
28. Deep venous thrombosis during therapy for Hodgkin's disease
29. Trombo-embolische complicaties van centraal-veneuze katheters
30. Pulmonary embolism in patients with upper-extremity DVT associated to venous central lines. A prospective study
31. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy
32. Complications of indwelling venous access devices in cancer patients
33. Upper extremity deep venous thrombosis in cancer patients with venous access devices - Prophylaxis with low molecular weight heparin
34. Central venous thrombosis: An early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study
35. Subcutaneously implanted central venous access devices in cancer patients
36. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies